









Markets
/
Stocks
/
nasdaq-staa
/

STAAR Surgical Co

STAA

17.580USD

+0.510+2.99%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

867.64MMarket Cap

LossP/E TTM



STAAR Surgical Co

17.580

+0.510+2.99%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of STAAR Surgical Co

Currency: USD Updated: 2026-02-06

Key Insights

STAAR Surgical Co's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 68 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 23.62.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

STAAR Surgical Co's Score

Industry at a Glance

Industry Ranking

68 / 205

Overall Ranking

179 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

STAAR Surgical Co Highlights

StrengthsRisks

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is -9.00, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 52.84M shares, decreasing 21.22% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 212.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.61.

Analyst Rating

Based on 11 analysts

Hold

Current Rating

23.625

Target Price

+38.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of STAAR Surgical Co is 8.31, ranking 51 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 94.73M, representing a year-over-year increase of 6.93%, while its net profit experienced a year-over-year increase of 10.98%.

Score

Industry at a Glance

Previous score

8.31

Change



Financials

9.85

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.91

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.79

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.39

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

STAAR Surgical Co's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of STAAR Surgical Co is 7.22, ranking 111 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -9.00, which is -1939.23% below the recent high of 165.61 and -574.67% above the recent low of -60.75.

Score

Industry at a Glance

Previous score

7.22

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 68/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of STAAR Surgical Co is 5.80, ranking 183 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 28.00, with a high of 30.75 and a low of 16.00.

Score

Industry at a Glance

Previous score

5.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Hold

Current Rating

23.625

Target Price

+34.69%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

STAAR Surgical Co

STAA

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of STAAR Surgical Co is 6.25, ranking 160 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 21.57 and the support level at 15.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.12

Change

0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.213

Sell

RSI(14)

27.277

Sell

STOCH(KDJ)(9,3,3)

15.245

Neutral

ATR(14)

0.800

Low Volatility

CCI(14)

-117.897

Sell

Williams %R

85.219

Oversold

TRIX(12,20)

-1.046

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

17.676

Sell

MA10

18.357

Sell

MA20

19.660

Sell

MA50

22.532

Sell

MA100

24.535

Sell

MA200

22.638

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of STAAR Surgical Co is 10.00, ranking 1 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 106.24%, representing a quarter-over-quarter increase of 5.76%. The largest institutional shareholder is The Vanguard, holding a total of 4.22M shares, representing 8.48% of shares outstanding, with 22.33% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Broadwood Capital, Inc.

15.02M

BlackRock Institutional Trust Company, N.A.

6.58M

-1.98%

The Vanguard Group, Inc.

Star Investors

4.26M

-2.78%

Yunqi Capital Limited

2.50M

State Street Investment Management (US)

1.91M

-4.59%

Balyasny Asset Management LP

1.81M

Magnetar Capital Partners LP

1.20M

Geode Capital Management, L.L.C.

1.17M

-1.59%

Goldman Sachs & Company, Inc.

863.00K

+634.18%

Sand Grove Capital Management LLP

829.12K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of STAAR Surgical Co is 5.57, ranking 81 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.08. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.